CSS LLC’s Madrigal Pharmaceuticals MDGL Stock Holding History

CSS LLC’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,900	Closed	-$123K	–	1040
2022 Q3	$123K	Buy	+1,900	New	+$132K	0.01%	806

Other funds holding MDGL

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CSS LLC's MDGL Position: Q4 2022 in Review

CSS LLC sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2022, closing a stake of 544 shares — an estimated $35K sold.

CSS LLC first reported a position in MDGL in Q3 2022 and held it in 1 quarter. The position peaked at $35K in Q3 2022. 189 funds tracked by Wall St. Rank hold MDGL as of Q4 2022.

CSS LLC reported no remaining Madrigal Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
CSS LLC sold 544 Madrigal Pharmaceuticals shares in Q4 2022, an estimated $35K.
CSS LLC first reported a position in Madrigal Pharmaceuticals in Q3 2022 and held it in 1 quarter.
CSS LLC's Madrigal Pharmaceuticals position peaked at $35K in Q3 2022.
189 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2022.

Based on CSS LLC's 13F filing for Q4 2022, filed 14 Feb 2023.